Exscientia (EXAI) Details Pipeline Prioritisation Strategy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Exscientia Details Pipeline Prioritisation Strategy
October 3, 2023 8:00 AM EDTConcentrating rapidly emerging pipeline on most differentiated, highest value oncology targets, including CDK7 and LSD1 programmes
Partnering or discontinuing internal development of programmes outside of core focus, including A2A and select discovery targets
Strategy will support continued investment into market-leading technology while maintaining cash runway well into 2026
Partnered pipeline continues to progress with achievement of first milestone for Sanofi collaboration and new collaboration with Merck KGaA
OXFORD, U.K.--(BUSINESS WIRE)-- Exscientia plc (Nasdaq:... More
